Pollution of aqueous, terrestrial, and airborne environments by microplastic particles is increasing, and their presence in foods and drinking water has recently been reported. Often, these particles are unintentionally ingested and are present in human stool samples, according to a study published in Annals of Internal Medicine.
These findings indicate the importance of optimizing infliximab dosage to a level that achieves efficacy without activating an immune response against the infliximab-TNF complex.
Cobitolimod is a first in class, toll-like receptor 9 (TLR9) agonist with local anti-inflammatory effects in the large intestine, which may promote mucosal healing.
The risk for type 2 diabetes was significantly higher for patients who received a diagnosis of IBD from 2003 through 2014 versus those diagnosed from 1977 through 1988 or from 1989 through 2002 (SIRs, 1.79 versus 1.47 and 1.48, respectively).
The association between disease activity and emotional processing biases may play a role in the higher rates of depression in patients with inflammatory bowel disease.
Smoking is not associated with a beneficial impact in disease outcomes in UC. Furthermore, we found no evidence that smoking cessation impacts adversely on subsequent clinical outcomes.
In terms of benefit and risk, biologics were both considered more beneficial and riskier than immunomodulators. Bowel resection was considered to be slightly more risky, but more beneficial than biologic treatment.
Crohn disease and ulcerative colitis comprise the 2 primary subtypes of inflammatory bowel diseases (IBD). IBD currently has no known cure and whose pathogenesis is not well understood. However, an increasing amount of research points to genetic risk factors combined with antibiotic use and changes in intestinal microbiota as triggers for the onset of IBD.1,2…
JAK inhibitors effectively induce clinical remission in patients with Crohn disease and clinical and endoscopic remission in patients with ulcerative colitis.
A meta-analysis of 13 randomized controlled trials found no association betweendipeptidyl peptidase-4 inhibitor use and inflammatory bowel disease risk in patients with type 2 diabetes.
Treatment with anti-TNFα agents for conditions other than inflammatory bowel disease may increase the risk of developing Crohn disease or ulcerative colitis.
